Vanguard reports 12.96M shares (5.16%) in BioCryst

BioCryst Pharmaceuticals Inc reports that Vanguard Capital Management beneficially owns 12,961,172 shares of Common Stock as of 03/31/2026, representing 5.16% of the class.

Rhea-AI Filing Summary

BioCryst Pharmaceuticals Inc reports that Vanguard Capital Management beneficially owns 12,961,172 shares of Common Stock as of 03/31/2026, representing 5.16% of the class.

The filing lists sole voting power of 1,825,410 shares and sole dispositive power over 12,961,172 shares. The Schedule 13G was signed by Ashley Grim on 04/29/2026.

Insights

Institutional Ownership Analyst

Vanguard Capital Management holds a passive >5% stake in BioCryst, disclosed on a Schedule 13G.

The filing shows beneficial ownership of 12,961,172 shares or 5.16% as of 03/31/2026. The holder reports sole dispositive authority and limited sole voting authority of 1,825,410 shares. This indicates investment-management control over disposition decisions while voting rights are substantially delegated or held across funds.

Cash‑flow treatment or planned disposition is not stated; subsequent filings would show any active changes in holdings.

Regulatory Compliance Specialist

The Schedule 13G filing follows passive investor disclosure rules under Section 13(g).

The statement identifies Vanguard Capital Management and affiliated business divisions and includes the required ownership breakdown and CUSIP 09058V103. The filing text cites SEC Release No. 34-39538, clarifying aggregation rules for affiliated accounts.

Investors should note the filing type signals passive intent; a Schedule 13D would be required if activism or acquisition intent arose.

Key Figures

Beneficial ownership: 12,961,172 shares Percent of class: 5.16% Sole voting power: 1,825,410 shares +2 more

5 metrics

Beneficial ownership 12,961,172 shares as of 03/31/2026

Percent of class 5.16% reported on Schedule 13G

Sole voting power 1,825,410 shares voting power reported in Item 4(c)(i)

Sole dispositive power 12,961,172 shares dispositive power reported in Item 4(c)(iii)

CUSIP 09058V103 BioCryst Common Stock identifier

Key Terms

Schedule 13G, sole dispositive power, beneficial ownership, CUSIP

4 terms

Schedule 13G regulatory

"reports beneficial ownership of 12,961,172 shares"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

sole dispositive power financial

"Sole power to dispose or to direct the disposition of: 12961172"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

beneficial ownership financial

"Amount beneficially owned: 12961172"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

CUSIP technical

"Common Stock 09058V103"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Vanguard Capital Management report in BioCryst (BCRX)?

Vanguard reports beneficial ownership of 12,961,172 shares, representing 5.16% of BioCryst common stock as of 03/31/2026. The filing is a Schedule 13G signed on 04/29/2026.

How much voting power does Vanguard hold in BioCryst?

Vanguard reports sole voting power for 1,825,410 shares and no shared voting power. The filing separately lists sole dispositive power over 12,961,172 shares.

Does the Schedule 13G indicate Vanguard plans to sell or buy more BCRX shares?

No. The Schedule 13G reports passive beneficial ownership and does not state plans to buy or sell. The filing type itself signals passive status rather than active acquisition or disposition intent.

Which entity or CUSIP is referenced in the filing for BioCryst shares?

The filing references BioCryst Pharmaceuticals Inc Common Stock with CUSIP 09058V103. The reporting person is Vanguard Capital Management, located at Malvern, Pennsylvania.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/29/2026 - 05:02 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

BioCryst Pharmaceuticals Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

09058V103

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 09058V103

1

Names of Reporting Persons

Vanguard Capital Management

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,825,410.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 12,961,172.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

12,961,172.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.16 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd. This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power. This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: BioCryst Pharmaceuticals Inc
(b)	Address of issuer's principal executive offices: 4505 Emperor Blvd, Suite 200, Durham, NC, 27703
Item 2.
(a)	Name of person filing: Vanguard Capital Management
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd,, Malvern, PA, 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 09058V103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 12961172
(b)	Percent of class: 5.16 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1825410
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 12961172
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Vanguard Capital Management, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Vanguard Capital Management

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	04/29/2026